TY - JOUR
T1 - Boosting therapeutic potency of antibodies by taming Fc domain functions
AU - Kang, Tae Hyun
AU - Jung, Sang Taek
N1 - Funding Information:
This work was supported by grants from the Basic Science Research Programs (2019R1F1A1059834 and 2019R1A4A1029000), the Bio & Medical Technology Development Program (2017M3A9C8060541), and the Pioneer Research Center Program (2014M3C1A3051460) through the National Research Foundation of Korea funded by the Ministry of Science and ICT.
Publisher Copyright:
© 2019, The Author(s).
PY - 2019/11/1
Y1 - 2019/11/1
N2 - Monoclonal antibodies (mAbs) are one of the most widely used drug platforms for infectious diseases or cancer therapeutics because they selectively target pathogens, infectious cells, cancerous cells, and even immune cells. In this way, they mediate the elimination of target molecules and cells with fewer side effects than other therapeutic modalities. In particular, cancer therapeutic mAbs can recognize cell-surface proteins on target cells and then kill the targeted cells by multiple mechanisms that are dependent upon a fragment crystallizable (Fc) domain interacting with effector Fc gamma receptors, including antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis. Extensive engineering efforts have been made toward tuning Fc functions by either reinforcing (e.g. for targeted therapy) or disabling (e.g. for immune checkpoint blockade therapy) effector functions and prolonging the serum half-lives of antibodies, as necessary. In this report, we review Fc engineering efforts to improve therapeutic potency, and propose future antibody engineering directions that can fulfill unmet medical needs.
AB - Monoclonal antibodies (mAbs) are one of the most widely used drug platforms for infectious diseases or cancer therapeutics because they selectively target pathogens, infectious cells, cancerous cells, and even immune cells. In this way, they mediate the elimination of target molecules and cells with fewer side effects than other therapeutic modalities. In particular, cancer therapeutic mAbs can recognize cell-surface proteins on target cells and then kill the targeted cells by multiple mechanisms that are dependent upon a fragment crystallizable (Fc) domain interacting with effector Fc gamma receptors, including antibody-dependent cell-mediated cytotoxicity and antibody-dependent cell-mediated phagocytosis. Extensive engineering efforts have been made toward tuning Fc functions by either reinforcing (e.g. for targeted therapy) or disabling (e.g. for immune checkpoint blockade therapy) effector functions and prolonging the serum half-lives of antibodies, as necessary. In this report, we review Fc engineering efforts to improve therapeutic potency, and propose future antibody engineering directions that can fulfill unmet medical needs.
UR - http://www.scopus.com/inward/record.url?scp=85075114343&partnerID=8YFLogxK
U2 - 10.1038/s12276-019-0345-9
DO - 10.1038/s12276-019-0345-9
M3 - Review article
C2 - 31735912
AN - SCOPUS:85075114343
SN - 1226-3613
VL - 51
JO - Experimental and Molecular Medicine
JF - Experimental and Molecular Medicine
IS - 11
M1 - 138
ER -